Crispr Therapeutics AG Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 7/14/2026)
| Balance Sheet | Total Assets | 2,265,243,000.00 | ROE | 84.84 % |
| Balance Sheet | Total Equity | 1,921,813,000.00 | ROA | -25.67 % |
| Cashflow | Capital Expenditures | -914,000.00 | P/FCF | -13.05 |
| Cashflow | Free Cash Flow | -345,928,000.00 | – | – |
| Cashflow | Operating Cash Flow | -345,014,000.00 | P/CF | -13.09 |
| Income | Earnings per Share (diluted) | -5.41 | Div. Yield | – |
| Income | Net Income | -581,599,000.00 | P/E | -7.76 |
| Income | Shares Outstanding | 89,925,100.00 | P/B | 2.35 |
| Income | Total Revenue | 3,510,000.00 | P/S | 1,286.62 |
Ratios calculated on: 10/14/2026
Company Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.crisprtx.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more